How Practice Fusion Makes Money

Nine-year-old Practice Fusion stole a march on larger competitors like Allscripts or McKesson by providing its EMR system for free to physicians, who receive government money for adopting digital records. The company, which has raised about $150 million from VCs, generates revenue from labs, pharmacies, and imaging centers whose services physicians can order via the EMR.

Nine-year-old Practice Fusion stole a march on larger competitors like Allscripts or McKesson by providing its EMR system for free to physicians, who receive government money for adopting digital records. The company, which has raised about $150 million from VCs, generates revenue from labs, pharmacies, and imaging centers whose services physicians can order via the EMR. It has also attracted pharmaceutical firms: Merck & Co. sponsors a check box on the EMR that asks whether government-recommended vaccines are required for the patient. This helps Merck boost vaccine sales, and to learn more about doctors’ behavior (and track outcomes). Physicians can also choose to use the EMR to remind patients to undergo certain tests or to take/refill their medication, offering opportunities for further Big Pharma sponsorship. Current deals, according to Orbimed’s Stephen Yecies, are category- rather than brand-specific, involving companies with large share of a particular market such as hypertension. It’s all in the name of better prevention – many doctors are now graded and, in some cases paid, according to meeting best-practice targets. Yet drug firms also pay to push brand-specific ads to doctors and users via the Practice Fusion software.

PF’s latest move is toward patients, with its Patient Fusion site; in August 2014 the company partnered with Vitals, which...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

BIO Notebook: MFN Pricing, Next-Gen Obesity R&D, FDA’s Rare Disease Hub & Reaction To Review Program

Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.

EY Recommends Focusing On Fundamentals, Waiting For Prime Deal Conditions

 
• By 

Government policy ramifications and tight financial markets mean it’s time to prepare strategically for a better business development environment, EY suggests.

Scholar Rock Shows Muscle-Building PoC In Obesity

 

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Ireland’s Got Biopharma Talent To Keep Leading The Pack

 
• By 

The country’s life sciences investment head tells Scrip that it is business as usual for the sector despite the rumblings from across the Atlantic.

More from Business

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By 

Wales-based group launches with $140m series A.

BIO Notebook: Policy Problems, ACIP’s Future, BI Is Popular, Makary On FDA-Industry Ties

 

Highlights from Day Two of the BIO International Convention include BIO officials raising concerns about Trump Administration policies, the future of ACIP, an interview with BI's head of global business development, and FDA Commissioner Martin Makary's view of the FDA-industry relationship.

Lilly Agrees To Acquire PCSK9 Base-Editing Partner Verve

 
• By 

Instead of opting in on Phase II-ready PCSK9-targeted VERVE-102, Lilly will buy its partner for up to $1.3bn. Analysts call the deal a bargain for Lilly, but fair to Verve.